Companies celebrate handover of 1000th ÄKTAprocess
Chalfont St Giles, UK and Laupheim, Germany – 14 April 2015 – GE Healthcare Life Sciences a provider of tools, technologies and services to the biopharmaceutical manufacturing industry and Rentschler Biotechnologie GmbH, a leading contract manufacturing and development organization (CDMO) for biopharmaceuticals, announced today a joint celebration to mark the handover of GE Healthcare’s 1000th ÄKTAprocess™ and the expansion of Rentschler’s biopharmaceutical manufacturing capabilities in Laupheim, Germany. ÄKTAprocess, GE’s automated process and manufacturing-scale chromatography system, has gone into operation as part of Rentschler’s recently expanded single-use manufacturing suite. GE biomanufacturing technologies such as the XDR 2000L bioreactor, the associated seed trains of 50, 200 and 500 L as well as the new ÄKTAprocess play a key role in Rentschler’s new single-use manufacturing line.
Peter Rogge, VP USP Production, Rentschler, commented, “This line will further enhance our ability to deliver high quality projects for companies around the globe and is providing increased capacity in Europe of next-generation manufacturing capabilities. GE continues to have the innovative tools and expertise to deliver the high quality products and services demanded by companies like us.”
Emmanuel Ligner, GM Global Commercial, BioProcess, added, “Rentschler has the depth of experience and high-quality infrastructure to support the manufacture of the most challenging complex biotherapeutics. I am delighted to formally hand over the 1000th ÄKTAprocess and to see the new single use line featuring the GE XDR 2000L. Our relationship with Rentschler began almost 20 years ago and we are proud to have been able to support their growth over so many years. We look forward to supporting them as they adapt and expand to meet the future needs of the industry.”
About Rentschler Biotechnologie
Rentschler is a CDMO with over 40 years proven track record in biopharmaceuticals. Focused on the utilization of mammalian cell lines, Rentschler’s long experience covers the development and production of recombinant proteins in compliance with international GMP standards. Rentschler’s customized solutions range from supporting drug candidate selection, cell line and process development capabilities as well as GMP production to comprehensive analytics and fill & finish. Rentschler’s state-of-the-art manufacturing facility includes bioreactors up to 3,000 L and aseptic filling lines for vials (including lyophilization) and prefilled syringes. The long-term experience with international regulatory affairs complements the offerings. Rentschler’s full-service concept allows flexibility on the individual project requirements. For more information go to: http://rentschler.de/en/home/
About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at www.gehealthcare.com.